Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
320.16
+4.62 (+1.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Today 13:19 EDT
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.
Via
Benzinga
Amgen (AMGN) Q3 2024 Earnings Call Transcript
October 30, 2024
AMGN earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
October 30, 2024
The company expects to have topline results from a Phase 2 study later this year.
Via
Investor's Business Daily
A Closer Look at Amgen's Options Market Dynamics
October 23, 2024
Via
Benzinga
Navigating 14 Analyst Ratings For Amgen
October 22, 2024
Via
Benzinga
Is Amgen Stock a Buy?
October 18, 2024
This biotech leader could be poised to rally higher.
Via
The Motley Fool
Looking Into Amgen's Recent Short Interest
October 17, 2024
Via
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
October 30, 2024
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data.
Via
Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
One of these players has split its stock in the past. The other one hasn't.
Via
The Motley Fool
In-Depth Examination Of 11 Analyst Recommendations For Amgen
October 14, 2024
Via
Benzinga
(AMGN) - Analyzing Amgen's Short Interest
September 30, 2024
Via
Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
October 27, 2024
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.
Via
Talk Markets
Topics
ETFs
2 Reliable Dividend Stocks You Can Buy and Hold Forever
October 26, 2024
There are reasons beyond the dividends to invest in these stocks.
Via
The Motley Fool
Top Stock Reports For Costco, Coca-Cola & T-Mobile US
October 25, 2024
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp., The Coca-Cola Co., and T-Mobile US, Inc., as well as a micro-cap stock Preformed Line Products...
Via
Talk Markets
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Via
Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
October 14, 2024
The analyst is closely watching MariTide, a potential monthly injection to treat obesity.
Via
Investor's Business Daily
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
October 13, 2024
It is Fall clean up time. Sell lagging and sagging companies.
Via
Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Via
Benzinga
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
October 11, 2024
Income stocks can be wise additions to your portfolio in any market environment.
Via
The Motley Fool
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
October 10, 2024
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
October 10, 2024
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Deere & Company as his final trade.
Via
Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
October 09, 2024
These longtime leading biotech stocks still have plenty of upside ahead.
Via
The Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
October 08, 2024
Investing in the most popular players in the space isn't the only valid approach.
Via
The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
October 06, 2024
These dividend stocks are great picks as the fall season gets underway.
Via
The Motley Fool
Should You Buy the Dip on This Top Growth Stock?
October 05, 2024
The biotech needs to overcome an issue most drugmakers face at some point.
Via
The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
October 02, 2024
Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.